Jiang Zefei, Wang Xiaodi
Center of Cancer, Academy of Military Medical Sciences, Beijing 100071, China; Email:
Zhonghua Wai Ke Za Zhi. 2015 Dec 1;53(12):895-900.
Endocrine therapy is one of the main treatment for hormone receptor positive breast cancer. In recent years, some of the critical results of clinical studies have been published, triggering a heat discussion. Guidelines and expert consensus have made appropriate updates based on some results. However, the selection and duration of the endocrine therapy for premenopausal women, the judgment of the menstrual conditions, the application of ovarian function suppression and the choice of endocrine drug combining with ovarian function suppress, and monitoring the endometrial thickness and hormone levels during therapy, as well as the endocrine therapy for postmenopausal patients and metastatic cancer are still controversial. Based on the evidence from study and clinical experience, this article will focus and discuss the ten hot issues.
内分泌治疗是激素受体阳性乳腺癌的主要治疗方法之一。近年来，一些临床研究的关键结果已发表，引发了热烈讨论。指南和专家共识已根据一些结果进行了适当更新。然而，绝经前女性内分泌治疗的选择和疗程、月经状况的判断、卵巢功能抑制的应用以及内分泌药物与卵巢功能抑制联合的选择，治疗期间子宫内膜厚度和激素水平的监测，以及绝经后患者和转移性癌症的内分泌治疗仍存在争议。基于研究证据和临床经验，本文将聚焦并讨论十个热点问题。
